Navigation Links
British Artificial Intelligence Firm Announces Exclusive License Agreement with Janssen for Clinical Stage Drug Candidates, Facilitated by Johnson & Johnson Innovation

LONDON, November 8, 2016 /PRNewswire/ --

BenevolentAI, a leading British artificial intelligence ("AI") company today announced significant progress in one of its key ambitions; to improve and innovate the drug development process using AI technology and provide the best medicines to the right patients.  BenevolentAI has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen Pharmaceutica NV ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by the Johnson & Johnson Innovation Centre in London.

BenevolentAI has acquired a license to a select number of novel clinical stage drug candidates and   their extensive related portfolio of   patents.  BenevolentAI scientists leveraged the AI technology to evaluate the potential of these small molecule compounds. The results indicate that there is strong promise to develop new medicines for hard to treat diseases.  

Under the terms of the license agreement, BenevolentAI will have the sole right to develop, manufacture and commercialise these novel drug candidates in all indications and in all territories. This agreement will enable BenevolentAI to accelerate its development pipeline and use its unique artificial intelligence technology to explore and provide a rich source of clinical data. BenevolentAI intends to begin late stage Phase IIb clinical trials in mid 2017. Financial terms were not disclosed.

Jackie Hunter, Board Director of BenevolentAI and CEO of BenevolentAI Bio, commented:

"We are delighted to have acquired rights to these compounds under a license agreement from Janssen. The agreement adds further depth to our clinical and pre-clinical development pipeline and marks a very exciting time for the role of artificial intelligence to benefit scientific discovery and humanity. The compounds come with a wealth of clinical and biological data that enables BenevolentAI to have further insights into the biology of diseases. Securing these novel clinical drug candidates perfectly aligns with our strategy of developing first-in-class and best-in-class stratified medicines to help patients with high unmet needs."

SOURCE BenevolentAI
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Invited to Present Chronic Pain Patient Observation Study at the British Pain Society Congress
2. Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Councils Education U.K. Alumni Award
3. Cannabis Science, Inc. (CBIS) In Final Negotiations To Acquire British Columbia Company That Has Submitted Marihuana For Medical Purposes License Application To Health Canada
4. Smithsonians "Bionic Man" Documentary Featuring the SynCardia Total Artificial Heart Earns British Film Award
5. News Update: After 555 Days On The SynCardia Artificial Heart, Stan Larkin Is Now At Home With His Donor Heart
6. TrueCare24 Unveils Artificial Intelligence-Driven Healthcare Platform
7. Eight of The Best Total Artificial Heart Centers Honored by SynCardia
8. Worlds Leading Artificial Heart Center, La Pitié Hospital, Paris, Celebrates 30 Years and 249 Implants of the SynCardia Total Artificial Heart
9. New York Times Posts Retro Report Documentary: The Total Artificial Heart - From 1st Implant to Worlds Most Used Artificial Heart
10. Global Artificial Tears Industry
11. Insulet Announces Development Partner for the OmniPod Artificial Pancreas
Post Your Comments:
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
(Date:9/12/2017)... 2017  Consumer reviews on the independent review site Consumer ... one company for hearing aids, ranking it higher than Miracle ... ... Consumers For Hearing Aids ... an online store that provides high performance, state-of-the-art, German-engineered hearing aids ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):